Background: Several medications prescribed commonly in the nursing home (NH) setting require monitoring, either to assess response to treatment, need for dose adjustment, or for adverse drug reactions. We aimed to review adherence to recommendations for monitoring in a single NH centre, through monitoring practices in 3 medication groupsestablished denosumab therapy, established thyroid replacement therapy (TRT) and direct oral anticoagulants (DOACs). Methods: A gold standard for monitoring was agreed upon by the investigators, with review of product characteristics and guidelines for each medication group, in addition to national and international guidelines for treatment. In relation to established denosumab therapy, it was agreed that the gold standard constituted checking serum calcium levels prior to administration. In relation to established TRT, the gold standard was set at annual thyroid stimulating hormone (TSH) tests. With DOAC therapy, the gold standard was annual monitoring of renal function. Pharmacy prescriptions and medication administration records were reviewed for all patients ≥65years. Electronic patient record of patients prescribed denosumab, TRT or DOAC were subsequently reviewed for recent serological investigations. Results: 43 patients were reviewed. 9 were prescribed TRT, 5 DOAC therapy and 12 denosumab therapy. 89% of patients on TRT (n = 8) had their TSH checked in the preceding year, while 100% of patients prescribed DOAC therapy had renal function checked in the preceding 6 months. With denosumab therapy, 58% (n = 7) had calcium levels assessed in the preceding 6 months. Conclusion: In this centre, the use of denosumab for treatment of osteoporosis has far exceeded the use of bisphosphonates, and the use of DOACs has replaced warfarin in relation to oral anticoagulation therapy. With the advent of newer therapies that improve ease of administration or reduce the need for frequent monitoring in a NH setting, there is a need for ongoing education and vigilance to adhere to newer monitoring guidelines.
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